STSS - NASDAQ
Sharps Technology, Inc.
$1.84
+1.1%Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
At a Glance
Live SnapshotSharps Technology, Inc. Management Team
Mr. Robert M. Hayes
Chief Executive Officer & Director
Compensation
$600,890
Mr. Andrew R. Crescenzo CPA
Chief Financial Officer
Compensation
$236,040
Mr. Frank Parrado
Corporate Controller
Sharps Technology, Inc. Insider Positioning
During the last 12 months, insiders have purchased $5.13M and sold $991K worth of STSS shares, resulting in $4.14M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
414.0K
844.90K
-845K
-$845K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
800.0K
5.13M
10.0K
146.15K
+5.0M
+$4.98M
Top Buyers
Danner Paul K
Director
$2.56M
Hayes Robert Michael
Director
$641K
Christiansen Soren Bo
Director
$513K
Monroe Jason L.
Director
$513K
Ruemler Timothy James
Director
$513K
Top Sellers
Falconx Holdings Ltd
10 Percent Owner
$519K
Saba Capital Management, L.P.
10 Percent Owner
$326K
Ruemler Timothy James
Director
$146K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.14M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
STSS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | September 23, 2025 | September 23, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | July 28, 2025 | July 28, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | February 11, 2025 | February 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | November 06, 2024 | November 06, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | September 04, 2024 | September 04, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | June 26, 2024 | June 25, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | November 07, 2023 | November 07, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.